California counties sue over painkiller marketing

by Paul Elias

Two California counties have filed a lawsuit accusing five drug companies of waging a campaign of deception to boost the sales of painkillers behind the nation's prescription drug addiction problem.

Orange and Santa Clara counties filed the suit Wednesday in Orange County Superior Court, alleging false advertising, and creating a public nuisance.

The five companies are Johnson & Johnson's Janssen Pharmaceuticals, Purdue Pharma, Actavis, Endo Health Solutions Inc., and Teva Pharmaceutical Industries' Cephalon Inc.

Much like the legal attack on tobacco companies two decades ago by many states, the current lawsuit accuses the of making misleading and false claims about the safety of products consumed annually by millions of Americans.

The lawsuit seeks to stop the marketing campaigns by the companies and demands unspecified damages.

5 /5 (1 vote)
add to favorites email to friend print save as pdf

Related Stories

Drug firms argue against $1.2B Arkansas judgment

Feb 27, 2014

(AP)—A lawyer for two drug companies told the Arkansas Supreme Court that the state improperly relied on federal regulations in a lawsuit that resulted in a $1.2 billion award over the companies' marketing of an antipsychotics ...

Teva says US is investigating Copaxone marketing

Feb 10, 2014

Teva Pharmaceutical Industries said Monday the federal government is investigating its marketing of its multiple sclerosis drug Copaxone and Parkinson's disease treatment Azilect.

Seattle taxi drivers sue ridesharing service

Mar 25, 2014

A Seattle-area taxi drivers organization has sued an app-based ridesharing service, alleging that Uber violates multiple laws and regulations, thus harming taxi drivers and the public.

Authorities in US sue Novartis in kickback scheme

Jan 09, 2014

Novartis Pharmaceuticals Corp. paid kickbacks to a specialty pharmacy in exchange for recommending refills of a blood transfusion drug it produces, according to an amended complaint filed Wednesday in a civil case brought ...

Recommended for you

FDA approves hard-to-abuse narcotic painkiller

Jul 25, 2014

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

Jul 25, 2014

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

Tough-to-abuse formulation of oxycodone approved

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe pain when other ...

EU regulator: Morning-after pill OK for all women

Jul 24, 2014

(AP)—A commonly used morning-after pill is suitable for use by heavier women, the European Medicines Agency said Thursday after a review of the evidence sparked by the French manufacturer's declaration that the drugs didn't ...

Physicians warned about counterfeit medical devices

Jul 24, 2014

(HealthDay)—Physicians should be aware of the prevalence and serious consequences associated with use of counterfeit medical devices, according to a letter to the editor published online July 20 in Lasers in ...

User comments